BR112014002200A2 - tratamento de câncer de mama - Google Patents

tratamento de câncer de mama

Info

Publication number
BR112014002200A2
BR112014002200A2 BR112014002200A BR112014002200A BR112014002200A2 BR 112014002200 A2 BR112014002200 A2 BR 112014002200A2 BR 112014002200 A BR112014002200 A BR 112014002200A BR 112014002200 A BR112014002200 A BR 112014002200A BR 112014002200 A2 BR112014002200 A2 BR 112014002200A2
Authority
BR
Brazil
Prior art keywords
breast cancer
cancer treatment
treatment
breast
cancer
Prior art date
Application number
BR112014002200A
Other languages
English (en)
Inventor
A Protter Andrew
Cochrane Dawn
Richer Jennifer
Original Assignee
Medivation Prostate Therapeutics Inc
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014002200(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Inc, Univ Colorado Regents filed Critical Medivation Prostate Therapeutics Inc
Publication of BR112014002200A2 publication Critical patent/BR112014002200A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
BR112014002200A 2011-07-29 2012-07-27 tratamento de câncer de mama BR112014002200A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
BR112014002200A2 true BR112014002200A2 (pt) 2017-03-07

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002200A BR112014002200A2 (pt) 2011-07-29 2012-07-27 tratamento de câncer de mama

Country Status (18)

Country Link
US (4) US9517229B2 (pt)
EP (4) EP2739153B1 (pt)
JP (2) JP6158180B2 (pt)
KR (1) KR101923250B1 (pt)
CN (1) CN103997894B (pt)
BR (1) BR112014002200A2 (pt)
CA (1) CA2843417C (pt)
CY (1) CY1121038T1 (pt)
DK (1) DK2739153T3 (pt)
EA (1) EA028452B1 (pt)
ES (1) ES2696074T3 (pt)
HK (2) HK1198867A1 (pt)
HU (1) HUE040524T2 (pt)
MX (1) MX359664B (pt)
PL (1) PL2739153T3 (pt)
PT (1) PT2739153T (pt)
SI (1) SI2739153T1 (pt)
WO (1) WO2013066440A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2739153T3 (en) * 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
CN109908114A (zh) 2012-09-26 2019-06-21 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TWI674897B (zh) 2013-04-17 2019-10-21 美商標誌製藥公司 藉二氫吡并吡化合物組合療法的癌症治療方法
EP3065549A4 (en) * 2013-11-07 2017-05-24 Deciphera Pharmaceuticals, LLC Methods for inhibiting tie2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
EP3148336B1 (en) * 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
AU2015360767A1 (en) * 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
CA3067585A1 (en) 2017-06-22 2018-12-27 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
CA3163051A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
ME01992B (me) * 2005-05-13 2012-10-30 Univ California Jedinjenje diarilhidantoina
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
PL3100727T3 (pl) * 2006-03-27 2019-01-31 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
KR20160027254A (ko) 2006-03-29 2016-03-09 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
CA2703635C (en) 2007-10-26 2017-06-27 Michael E. Jung Diarylhydantoin compounds as androgen receptor modulators
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
SI2297359T1 (sl) 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
ES2535466T3 (es) 2009-02-24 2015-05-11 Medivation Prostate Therapeutics, Inc. Compuestos específicos de diariltiohidantoína
WO2010118354A1 (en) 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
WO2011022316A1 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
EP2685988A4 (en) 2011-03-15 2014-08-20 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH ANTHRACYCLIN THERAPY
DK2739153T3 (en) * 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
AU2012345789B2 (en) 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
WO2014031164A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
AU2015360767A1 (en) 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
CN103997894B (zh) 2016-08-24
HK1198867A1 (en) 2015-06-19
US10111861B2 (en) 2018-10-30
WO2013066440A1 (en) 2013-05-10
JP2017141269A (ja) 2017-08-17
WO2013066440A9 (en) 2013-07-18
EP3430907A1 (en) 2019-01-23
PT2739153T (pt) 2018-11-28
HK1201413A1 (en) 2015-09-04
ES2696074T3 (es) 2019-01-14
US9517229B2 (en) 2016-12-13
DK2739153T3 (en) 2018-12-03
PL2739153T3 (pl) 2019-04-30
MX359664B (es) 2018-10-05
KR20140107174A (ko) 2014-09-04
CA2843417C (en) 2018-08-21
EP2739153A4 (en) 2015-03-11
HUE040524T2 (hu) 2019-03-28
MX2014001218A (es) 2014-08-22
EP3791724A1 (en) 2021-03-17
EP2739153A1 (en) 2014-06-11
US20210069154A1 (en) 2021-03-11
KR101923250B1 (ko) 2018-11-28
US20170087132A1 (en) 2017-03-30
EA201400178A1 (ru) 2014-11-28
CA2843417A1 (en) 2013-05-10
US20190262315A1 (en) 2019-08-29
CN103997894A (zh) 2014-08-20
US20140296312A1 (en) 2014-10-02
CY1121038T1 (el) 2019-12-11
JP2014524934A (ja) 2014-09-25
SI2739153T1 (sl) 2018-12-31
EP2739153B1 (en) 2018-08-22
JP6158180B2 (ja) 2017-07-05
EA028452B1 (ru) 2017-11-30
EP3610731A1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
BR112014002200A2 (pt) tratamento de câncer de mama
IL267242B (en) Cancer treatment
HK1213444A1 (zh) 癌症的治療
BR112014007603A2 (pt) métodos de tratamento do câncer
IL237558A0 (en) Methods for treating locally advanced breast cancer
HK1254859A1 (zh) 治療乳腺癌的方法
DK2707030T3 (da) Cancerbehandlinger
BR112014012880A2 (pt) tratamento imunogênico do câncer
BR112013011659A2 (pt) métodos de tratamento do câncer
HK1214128A1 (zh) 癌症的治療
SMT201600235B (it) Predittori per il trattamento del cancro
GB201217892D0 (en) Treatment of cancer
HK1210023A1 (en) Cancer treatment
HK1204956A1 (en) Treatment of cancer
EP2802351A4 (en) METHOD OF TREATING BREAST CANCER
BR112012030907A2 (pt) bomba de mama
EP2888594A4 (en) METHOD OF DETERMINING TREATMENT FOR USE AGAINST BREAST CANCER
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201106630D0 (en) Cancer therapy
GB201222563D0 (en) Cancer treatment
GB201217890D0 (en) Treatment of cancer
BR112015008366A2 (pt) método de tratamento de câncer
GB201208296D0 (en) Treatment of cancer
GB201118220D0 (en) Cancer therapy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 47/28 , A61K 31/17

Ipc: A61K 31/4184 (2006.01), A61K 31/4166 ¢...!

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B25G Requested change of headquarter approved

Owner name: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY COMPANY (US) ; MEDIVATION PROSTATE THERAPEUTICS LLC (US)